StockNews.com initiated coverage on shares of Akari Therapeutics (NASDAQ:AKTX – Free Report) in a research note issued to investors on Sunday. The firm issued a sell rating on the biopharmaceutical company’s stock.
Akari Therapeutics Trading Down 2.6 %
NASDAQ:AKTX opened at $2.24 on Friday. The firm has a fifty day simple moving average of $2.81 and a 200-day simple moving average of $2.85. Akari Therapeutics has a 12 month low of $1.08 and a 12 month high of $4.40.
About Akari Therapeutics
Further Reading
- Five stocks we like better than Akari Therapeutics
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- Rocket Lab is the Right Stock for the Right Time
- What Are Dividends? Buy the Best Dividend Stocks
- SoundHound AI Will Advance By Triple Digits in 2025: Here’s Why
- Quiet Period Expirations Explained
- Celsius Holdings: Big Drop, Big Opportunity? Analysts Say Yes
Receive News & Ratings for Akari Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Akari Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.